1. Volume 386, Issue 9999, Pages 1156-1164 (September 2015)
Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial 
Prof Kathy Pritchard-Jones, MD, Christophe Bergeron, MD, Beatriz de Camargo, MD, Marry M van den Heuvel-Eibrink, MD, Tomas Acha, MD, Jan Godzinski, MD, Foppe Oldenburger, MD, Liliane Boccon-Gibod, MD, Prof Ivo Leuschner, MD, Prof Gordan Vujanic, MD, Bengt Sandstedt, MD, Jan de Kraker, MD, Harm van Tinteren, PhD, Norbert Graf, MD 
The Lancet 
Volume 386, Issue 9999, Pages (September 2015)
DOI: /S (14)
Copyright © 2015 Pritchard-Jones et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
AVD=actinomycin plus vincristine plus doxorubicin. AV2=actinomycin plus vincristine only (no doxorubicin).
The Lancet  , DOI: ( /S (14) )
Copyright © 2015 Pritchard-Jones et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2
Kaplan-Meier survival curves for event-free survival and overall survival
Data from the intention-to-treat population for event-free survival (A) and overall survival (B) and from the per-protocol population for event-free survival (C) and overall survival (D). EFS=event-free survival. OS=overall survival. Per-protocol population includes patients who had eligible tumour stage and histology according to review pathology, and correctly received their assigned treatment.
The Lancet  , DOI: ( /S (14) )
Copyright © 2015 Pritchard-Jones et al. Open Access article distributed under the terms of CC BY Terms and Conditions